Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Akshay Sharma, Neel S. Bhatt, Andrew St. Martin, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 3, pp. e185-e193
Open Access | Times Cited: 335

Showing 1-25 of 335 citing articles:

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 262
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Per Ljungman, Rafael de la Cámara, Małgorzata Mikulska, et al.
Leukemia (2021) Vol. 35, Iss. 10, pp. 2885-2894
Open Access | Times Cited: 207
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
Mounzer Agha, Maggie Blake, Charles Chilleo, et al.
Open Forum Infectious Diseases (2021) Vol. 8, Iss. 7
Open Access | Times Cited: 147
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Aakash Desai, Justin F. Gainor, Aparna Hegde, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 5, pp. 313-319
Open Access | Times Cited: 133
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety
Nicoletta Luxi, Alexia Giovanazzi, Annalisa Capuano, et al.
Drug Safety (2021) Vol. 44, Iss. 12, pp. 1247-1269
Open Access | Times Cited: 124
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
Rabah Redjoul, Anne Le Bouter, Florence Beckerich, et al.
The Lancet (2021) Vol. 398, Iss. 10297, pp. 298-299
Open Access | Times Cited: 116
COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 108
Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
Mounzer Agha, Maggie Blake, Charles Chilleo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 105
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Jason D. Goldman, Philip C. Robinson, Thomas S. Uldrick, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002630-e002630
Open Access | Times Cited: 105
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 105
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne M. Spanjaart, Per Ljungman, Rafael de la Cámara, et al.
Leukemia (2021) Vol. 35, Iss. 12, pp. 3585-3588
Open Access | Times Cited: 98
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
Rabah Redjoul, Anne Le Bouter, Vincent Parinet, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 10, pp. e681-e683
Open Access | Times Cited: 74
Administration of COVID-19 vaccines in immunocompromised patients
Manica Negahdaripour, Mojtaba Shafiekhani, Seyed Mohammad Iman Moezzi, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108021-108021
Open Access | Times Cited: 72
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
Joanne S. K. Teh, Julien Coussement, Zoe C. F. Neoh, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2014-2034
Open Access | Times Cited: 70
Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential
Ikram Hussain, Gabriel Liu Yuan Cher, Muhammad Abbas Abid, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 68
Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study
Ekaterini Goudouris, Fernanda Pinto‐Mariz, Leonardo Oliveira Mendonça, et al.
Journal of Clinical Immunology (2021) Vol. 41, Iss. 7, pp. 1479-1489
Open Access | Times Cited: 66
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients
Noga Shem‐Tov, Ronit Yerushalmi, Ivetta Danylesko, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 4, pp. 884-891
Open Access | Times Cited: 65
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis
Son Tran, Tony H. Truong, Aru Narendran
European Journal of Cancer (2021) Vol. 159, pp. 259-274
Open Access | Times Cited: 65
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Alessandro Busca, Jon Salmanton‐García, Paolo Corradini, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2427-2433
Open Access | Times Cited: 64
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
Francesco Passamonti, Alessandra Romano, Marco Salvini, et al.
British Journal of Haematology (2021) Vol. 195, Iss. 3, pp. 371-377
Open Access | Times Cited: 63
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, et al.
American Journal of Hematology (2021) Vol. 97, Iss. 1, pp. 30-42
Open Access | Times Cited: 61
A Systematic Review and Meta-Analysis of Inpatient Mortality Associated With Nosocomial and Community COVID-19 Exposes the Vulnerability of Immunosuppressed Adults
Mark Ponsford, Tom Ward, Simon Stoneham, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy
Roni Tamari, Ioannis Politikos, David A. Knorr, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 577-585
Open Access | Times Cited: 58
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
Christian Buske, Martin Dreyling, Alberto Álvarez‐Larrán, et al.
ESMO Open (2022) Vol. 7, Iss. 2, pp. 100403-100403
Open Access | Times Cited: 51
Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
Alice S. Huang, Caroline Cicin‐Sain, Chloé Pasin, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 4, pp. 214.e1-214.e11
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top